YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Cancer Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline small molecule developed as a selective inhibitor of hypoxia-inducible factor-1α (HIF-1α), and also functions as a soluble guanylyl cyclase (sGC) activator. YC-1 inhibits HIF-1α expression at the post-transcriptional level, reducing hypoxia-induced gene expression in tumor cells (APExBIO, product page). The compound suppresses tumor growth, angiogenesis, and vascularization in vivo, displaying an IC₅₀ of 1.2 μM for HIF-1 transcriptional activity. YC-1 is highly soluble in DMSO (≥30.4 mg/mL), insoluble in water, and is supplied by APExBIO for research use only. Its dual mechanism enables broad utility in cancer, hypoxia, and cGMP pathway research (Elama et al., 2022).

Biological Rationale

Hypoxia is a hallmark of solid tumors and drives tumor progression via stabilization of HIF-1α, a transcription factor that upregulates genes for survival, angiogenesis (especially VEGF), and metastasis under low oxygen. Inhibiting HIF-1α disrupts these adaptive responses and is a validated anticancer strategy (Elama et al., 2022). YC-1 was developed to target this pathway, directly modulating HIF-1α protein levels and activity. Additionally, YC-1's activation of sGC increases cyclic GMP (cGMP), influencing vascular tone and platelet aggregation, relevant to both tumor biology and circulatory disorders (see extended application guide). This dual action allows researchers to interrogate the crosstalk between hypoxia signaling and cGMP-mediated pathways in cancer and vascular research.

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

• HIF-1α Inhibition: YC-1 downregulates HIF-1α protein, acting post-transcriptionally to block HIF-1α accumulation under hypoxia (APExBIO).
• Suppression of HIF-1 Target Genes: Reduced HIF-1α leads to decreased expression of genes such as VEGF and GLUT1, impairing tumor angiogenesis and adaptation (Elama et al., 2022).
• sGC Activation: YC-1 stimulates soluble guanylyl cyclase, increasing cGMP production. This modulates vascular tone, inhibits platelet aggregation, and impacts cell signaling (YC-1 application guide).
• Antineoplastic Effects: In vivo, YC-1 reduces tumor size and microvessel density, confirming anti-angiogenic and anti-proliferative potential (recent mechanistic insights).

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity with an IC₅₀ of 1.2 μM in cell-based reporter assays (APExBIO).
• In vivo, YC-1 treatment yields smaller, less vascularized tumors with reduced HIF-1α and VEGF expression (https://doi.org/10.1016/j.saa.2021.120420).
• YC-1 activates soluble guanylyl cyclase, elevating cGMP levels and inhibiting platelet aggregation in vitro (workflow guide).
• YC-1 is highly soluble in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), but insoluble in water. Purity is ≥98% (https://www.apexbt.com/yc-1.html).
• Validated in workflows for cell viability, cytotoxicity, and hypoxia pathway assays, with robust reproducibility in multiple labs (scenario-based guidance).

Applications, Limits & Misconceptions

• Cancer Research: YC-1 is used to inhibit hypoxia signaling and angiogenesis in cancer cell models (review of mitochondrial impacts).
• Vascular Biology: Its sGC activation enables studies in vascular contractility and platelet function.
• Apoptosis & Cell Stress: YC-1 is applied in apoptosis, mitochondrial quality control, and oxidative stress research.

Common Pitfalls or Misconceptions

• YC-1 is not water-soluble; it must be dissolved in DMSO or ethanol for biological assays (APExBIO).
• It is not suitable for diagnostic or clinical use—research use only.
• Long-term storage of stock solutions is discouraged due to stability concerns; prepare fresh solutions as needed.
• Effects attributed to sGC activation may be confounded by concurrent HIF-1α inhibition—controls are required to deconvolute mechanisms.
• YC-1 does not inhibit all hypoxia pathways; its primary effect is via HIF-1α, not HIF-2α or other oxygen sensors.

This article extends the methodological detail of "Revolutionizing Hypoxia and Cancer Research: Strategic Developments with YC-1" by providing explicit solubility, storage, and workflow parameters. For a mechanistic focus on mitochondrial impacts, see "YC-1: Unveiling Its Role in Hypoxia Signaling and Mitochondrial Health". For scenario-driven troubleshooting and workflow optimization, see "Scenario-Driven Solutions with YC-1".

Workflow Integration & Parameters

• Solubility: Dissolve YC-1 at ≥30.4 mg/mL in DMSO or ≥16.2 mg/mL in ethanol. Do not use water as a solvent.
• Working Concentrations: Typical in vitro concentrations range from 0.1 to 30 μM; IC₅₀ for HIF-1 inhibition is 1.2 μM (cell-based, 24–48 h exposure, 37°C, normoxic/hypoxic conditions).
• Storage: Store the crystalline solid at room temperature in a desiccated environment. Use freshly prepared solutions; avoid storage beyond 24 hours.
• Controls: Include both normoxic and hypoxic controls, and consider sGC/cGMP pathway inhibitors to parse pathway specificity.
• Assay Compatibility: Validated for cell viability, cytotoxicity, hypoxia-responsive reporter, and cGMP assays.

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, available as SKU B7641 from APExBIO, is a robust research tool for dissecting hypoxia signaling and cGMP pathways. Its dual inhibition of HIF-1α and activation of soluble guanylyl cyclase enables multi-faceted experimental designs in oncology and vascular biology. While non-clinical, its reproducibility, purity (≥98%), and defined solubility parameters support advanced research applications. Future work includes expanding its use in neuroprotection, metabolism, and combinatorial drug screening (Elama et al., 2022).